News

Eli Lilly: Another Not-To-Miss Dip
Eli Lilly's stock dipped after drug trial results, but strong Q2 2025 earnings and market position make it a strong buy. Read ...
GLP-1 race heats up: Where Eli Lilly stands after weak trial data
Eli Lilly's (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein ...
Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker
Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.
MarketBeat on MSN10h
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
This week, drugmakers had a scare when President Trump threatened to levy tariffs of up to 250% on imported pharmaceuticals.
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...
Eli Lilly raises 2025 revenue guidance to $60B-$62B while expanding GLP-1 pipeline and production
Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...